z-logo
Premium
Antibacterial efficacy and pharmacokinetic evaluation of sanguinarine in common carp ( Cyprinus carpio ) following a single intraperitoneal administration
Author(s) -
Ling F,
Wu ZQ,
Jiang C,
Liu L,
Wang GX
Publication year - 2016
Publication title -
journal of fish diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 85
eISSN - 1365-2761
pISSN - 0140-7775
DOI - 10.1111/jfd.12433
Subject(s) - cyprinus , aeromonas hydrophila , pharmacokinetics , common carp , carp , aquaculture , biology , kidney , intraperitoneal injection , pharmacology , spleen , grass carp , fish farming , veterinary medicine , medicine , fishery , endocrinology , fish <actinopterygii> , immunology
Sanguinarine (SA), with antimicrobial and antiparasitic activities against fish pathogens, exhibits great potential commercial use in aquaculture. However, little information on pharmacokinetics of SA restricts further application in aquaculture. In this study, pharmacokinetics of SA in common carp ( Cyprinus carpio ) following a single intraperitoneal administration [10 mg kg −1 BW (body weight)] was evaluated by high‐performance liquid chromatography (HPLC). The peak concentration ( C max ) of SA in kidney was 11.8 μg g −1 , which was higher than in other tissues and plasma. The terminal half‐life in fish tissue and plasma was as follows: 42.3 h (kidney) > 37.2 h (liver) > 20.1 h (gill) > 18.8 h (muscle) > 10.9 h (spleen) > 10.0 h (plasma). Additionally, we determined the bacterial loads in tissues of common carp infected with Aeromonas hydrophila after i.p. administration of SA at 0, 5, 10 and 20 mg kg −1 BW. The results showed that i.p. administration of SA at 10 mg kg −1 BW significantly enhanced antibacterial efficacy against A. hydrophila , where the antibacterial ratio in the gill, kidney, spleen and liver on day 5 was 95.13%, 93.33%, 90.09% and 92.82%, respectively. Overall, these results suggested the potential of SA to treat A. hydrophila infection in common carp farming industry.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here